If there is a perceived erosion of the blockbuster model, rest assured that pharmaceutical and biotech companies – large and small – are hot on the trail for the next wave of blockbusters. And while small companies certainly have a role to play, Big Pharma still has the muscle power and capital to shape the future of drug development.

Broadening drug development from small molecules to biologics is a trend that’s been growing for the last 10 years. Most Big Pharma players now have a healthy pipeline of biologics in the works. And what I think is most exciting, is that every time a new biologic pathway is discovered, possibilities expand for small molecule drugs. It will be interesting to see what’s in store for the future…